logo ☰

Faculty Directory

Dr. Rahul K. Verma

Assistant Professor (Scientist-D)

Pharmaceutical Nanotechnology and Drug delivery systems. Development of nanoparticulate delivery systems and biomaterials for receptor based targeting, controlled release and depot effect of therapeutic agents/vaccine to their site of action. Designing of polymeric particulate delivery systems (Nano and micro systems) using Supercritical fluid technology, spray drying, spray freeze drying, and Microfluidizer techniques. Preclinical therapeutic and toxicological evaluation in cells lines and animal models.

CONTACT INFORMATION :

Research Interest

    • Our research is aimed at developing safe, efficient, and clinically viable biomaterials and nanoparticulate delivery systems for targeting, controlled release and depot effect of therapeutic agents/vaccine to their site of action.
    • Delivery of therapeutic agents for the treatment of lung and systemic diseases via dry powder inhalation (DPIs), particularly for tuberculosis and lung cancer.
    • Designing, development, and evaluation of polymeric particulate drug delivery systems (microparticles, Nanoparticles, Porous Nanoparticle Aggregates (PNAP)) for Pulmonary, Nasal and transdermal administration.  
    • Development of antigen and adjuvant loaded nano-carrier systems for immunization. 
    • In vitro and in vivo evaluation of novel drug delivery platforms, preclinical drug evaluation in cell lines animal models.

Research Highlights

empty! record not found

PhD Students

  • Mr. Ankur Sharma

    Email: ankur.ph14208@inst.ac.in

    Reg. No.: PH14208

    Working Since Jul, 2014

Project - JRF/SRF

  • Kalpesh Vaghasiya

    Email: kalpesh.rp141621@inst.ac.in

    Reg. No.: None

    Working Since Mar, 2015

  • Eupa Ray

    Email: eupa.rp10161@inst.ac.in

    Reg. No.: phd

    Working Since May, 2020

empty! record not found

  1. Dynamic mucus penetrating microspheres for efficient pulmonary delivery and enhanced efficacy of host defense peptide (HDP) in experimental tuberculosis: Sharma A,Vaghasiya K,Gupta P,Singh AK,Gupta UD,Verma RK*, (2020) Journal of Controlled Release, 324: 17-33 (IF:8:00). DOI: https://doi.org/10.1016/j.jconrel.2020.05.013

  2. Targeted pulmonary delivery of Epigallocatechin gallate (EGCG), a green tea polyphenol controls the growth of Mycobacterium tuberculosis by enhancing the autophagy and supressing bacterial bu: Sharma A,Vaghasiya K,Ray E,Gupta P,Gupta UD,Singh AK,Verma RK*, (2020) ACS Biomaterials Science & Engineering, . DOI: Accepted (IF:4.51)

  3. Matrix metalloproteinase responsive mesoporous silica nanoparticles cloaked with cleavable-protein for “Self-actuating” on-demand controlled drug delivery for cancer therapy: Vaghasiya K,Ray E, Sharma A,KatareOP,Verma RK*, (2020) ACS Applied Bio Materials, (Accepted).

  4. In vitro anti-tumoral and anti-bacterial activity of octamolybdate cluster-based hybrid solid incorporated with copper picolinate complex: Arti Joshi,Ruby Gupta, Kalpesh Vaghasiya,Rahul Kumar Verma,Deepika Sharma,Monika Singh*, (2020) ACS Applied Bio Materials, (Accepted).

  5. Silymarin encapsulated nanoliquid crystals for improved activity against beta amyloid induced cytotoxicity: Singh A, Kumar A, Verma RK, Shukla R, (2020) International Journal of Biological Macromolecules, 7;149: 1198-1206 (IF:4.8). DOI: doi: 10.1016/j.ijbiomac.2020.02.041.

  6. Inhalation delivery of host defence peptides (HDP) using nano-formulation strategies: A pragmatic approach for therapy of pulmonary ailments.: Adlakha S, Sharma A, Vaghasiya K, Ray E,Verma RK*, (2020) Current Protein & Peptide Science, 21: 369 - 378 (IF:2.37). DOI: 10.2174/1389203721666191231110453

  7. Heparin encapsulated metered-dose topical “Nano-spray gel” liposomal formulation ensures rapid on-site management of frostbite injury by inflammatory cytokines scavenging: Vaghasiya K, Sharma A, Kumar K, Ray E, Adhlakha S, Katare OP, Hota S,Verma RK*, (2019) ACS Biomaterials Science & Engineering, 5: 6617-6631 (IF:4.51). DOI: https://doi.org/10.1021/acsbiomaterials.9b01486

  8. Polycaprolactone based nano-carrier for co-administration of moxifloxacin and rutin and its in-vitro evaluation for sepsis: Handa M, Sharma A,Verma RK,Shukla R, (2019) Journal of Drug Delivery Science and Technology, 56: 101286 (IF:2.60). DOI: 10.1016/j.jddst.2019.101286

  9. Alginate Micro-Spheres elicit innate Th1-inflammatory response in macrophages leading to bacillary killing: Vaghasiya K, Eram A, Sharma A, Ray E, Adlakha S,Verma RK*, (2019) AAPS PharmSciTech, 20(6): 241 (IF:2.82). DOI: 10.1208/s12249-019-1458-0

  10. Temperature/pH triggered PNIPAM based Smart nanogel system loaded with Anastrozole delivery for application in cancer chemotherapy AAPS PharmScitech: Handa M, Sharma A,Verma RK,Shukla R, (2019) AAPS PharmSciTech, 20(5): 213 (IF:2.82). DOI: 10.1208/s12249-019-1410-3

  11. Nanostructured silver decorated hollow silica and their application in treatment of microbial contaminated water at room temperature: Baruah A, Vaghasiya K, Ganguli AK,Verma RK ,Jha M, (2019) New Journal of Chemistry, 458(1): 84-89 (IF:3.06). DOI: 10.1039/C9NJ01049A

  12. Mycobactericidal activity of some micro-encapsulated synthetic Host Defense peptides (HDP) by expediting the permeation of antibiotic: A new paradigm of drug delivery for tuberculosis: Sharma A, Vaghasiya K, Gupta P, Gupta UD, Verma RK*, (2019) International Journal of Pharmaceutics, 10;558: 231-241 (IF:4.21). DOI: 10.1016/j.ijpharm.2018.12.076

  13. Nano-encapsulated HHC10 host defense peptide (HDP) reduces the growth of Escherichia coli via multimodal mechanisms.: Sharma A, Vaghasiya K, Ray E,Verma RK, (2018) Artificial Cells, Nanomedicine, and Biotechnology, 23: 1-10 (IF:4.46). DOI: 10.1080/21691401.2018.1489823

  14. Hollow ZnO from assembly of nanoparticles: photocatalytic and antibacterial activity: Zaidi Z, Vaghasiya K,Vijay A,Sharma M,Verma RK ,Vaidya S, (2018) Journal of Material Science, 53: 14964–14974 (IF:3.44). DOI: 10.1007/s10853-018-2715-4

  15. Timing feedback-inhibition of the reproductive hormone axis for male contraception: Malik R, Tondwal S, Venkatesh K.S, Gupta G, Shanker K,Verma RK,Misra A, (2018) Molecular Medicine (Indian Society for the Study of Reproduction and Fertility), 117-130.

  16. Lysosomal targeting strategies for design and delivery of bioactive for therapeutic interventions Journal of Drug Targeting: S harma A, Vaghasiya K, Ray E,Verma RK, (2018) Journal of Drug Targeting, 26: 208–221 (IF:3.40). DOI: 10.1080/1061186X.2017.1374390

  17. Reclaiming hijacked phagosomes: Hybrid nano-in-micro encapsulated MIAP peptide ensures host directed therapy by specifically augmenting phagosome-maturation and apoptosis in TB infected macro: Sharma A, Vaghasiya K, Gupta P,Singh A,Gupta UD,Verma RK*, (2018) International Journal of Pharmaceutics, 536 (1): 50-62 (IF:4.21). DOI: 10.1016/j.ijpharm.2017.11.046

  18. Hollow ZnO from assembly of nanoparticles: photocatalytic and antibacterial activity,: Z Zaidi, K Vaghasiya, A Vijay, M Sharma, RK Verma,Sonalika Vaidya, (2018) Journal of Materials Science, 53 (21): 14964-14974. DOI: 10.1007/s10853-018-2715-4

  19. Hybrid Nano-in-Micro systems for lung delivery of Host Defence Peptides (HDP) as adjunct therapeutics for Pulmonary TB: Sharma A,Verma RK, (2017) Journal of aerosol medicine and pulmonary drug delivery, 31 (2): A17-A17 (IF:2.86).

  20. Supplementation of host response by targeting nitric oxide to the macrophage cytosol is efficacious in the hamster model of visceral leishmaniasis and efficacy of amphotericin B: Pandya SK, Khare P, Tiwari B, Srinivasrao D, Dube A, Goyal N, Misra A, (2016) International Journal for Parasitology, 6(2): 125-132 (IF-3:00). DOI: 10.1016/j.ijpddr.2016.01.001

  21. Misdiagnosis Murder: disguised TB or Lung cancer: Vaghasiya K, Sharma A, (2016) Pulmonary Research and Respiratory Medicine, 3 (02): e5-e6. DOI: 10.17140/PRRMOJ-3-e006

  22. Inhalable microspheres with hierarchical pore size for tuning the release of biotherapeutics in lungs Microporous and Mesoporous Materials: Sharma A, Vaghasiya K,Verma RK, (2016) Microporous and Mesoporous Materials, 235: 195-203 (IF:4.2). DOI: 10.1016/j.micromeso.2016.08.009

  23. Lung Delivery of Anti-microbial Peptides (AMP) Using Dry Powder Inhalable Microspheres for Treatment of Pulmonary Tuberculosis: Respiratory drug delivery proceedings, (2015) 2: 339-344.

  24. Regulation of cell death by intracellular delivery of nitric oxide to macrophages infected with virulent or avirulent Mycobacterium tuberculosis: Verma RK, Misra A, (2015) Tuberculosis (Elsevier), 95 (5): 625-628 (IF:3:00). DOI: 10.1016/j.tube.2015.05.002

  25. Inhalation drug delivery devices: technology update: Ibrahim M, Garcia-Contreras L.,Verma RK, (2015) Medical Devices: Evidence and Research., 131-139 (IF:3:00). DOI: 10.2147/MDER.S48888

  26. Surface coating of doxorubicin loaded nanocapsule with alginate enhances its therapeutic efficacy through Th1 type immune response in Leishmania donovani infected hamsters: Kansal S,Tandon R, Verma A, Misra P, Choudhary AK, Verma PRP, Dube A, Mishra PR, (2014) British journal of Pharmacology (BJP), 171(17): 4038–4050 (IF:6.81). DOI: 10.1111%2Fbph.12754

  27. In Vitro Comparison of Two Nasal Delivery Devices to Administer Dry Powders: Garcia-Contreras L, (2014) Respiratory Drug Delivery (RDD), 156-161.

  28. Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill M. tuberculosis: Agrawal AK, Singh AK, Mohan M, Gupta A, Gupta P, Gupta UD, Verma PRP, Misra A, (2013) Tuberculosis ( Elsevier), 93(4): 412-417 (IF:3.00). DOI: 10.1016/j.tube.2013.02.012

  29. Inhaled microparticles containing clofazimine are efficacious in the treatment of experimental tuberculosis in mice: Germishuizen WA, Motheo MP, Agrawal AK, Singh AK, Mohan M, Gupta P, Gupta UD, Cholo M, Anderson R, Misra A,Fourie PB, (2013) Antimicrobial Agents and Chemotherapy (AAC), 57(2): 1050-1052. DOI: 10.1128/AAC.01897-12

  30. Bacterial DNA gyrase is not the target of quinoline based anti-tubercular compounds International Research: Tripathy RK, Paul MK, Nayyar A, Jain R,Mukhopadhayay AK, (2013) journal of Pharmacy(IJRP), 4(1): 284-292..

  31. Investigations on Alternate Approach to Target Mannose Receptors on Macrophages using 4-Sulfated N-Acetyl Galactosamine more Efficiently as Compared to Mannose Decorated Liposomes : An Applic: Singodia D, Verma A,Mishra PR, (2012) Nanomedicine-Nanotechnology, Biology and Medicine, 8(4): 468-477.. DOI: 10.1016/j.nano.2011.07.002

  32. Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to Rhesus macaques: Mukker JK, Singh RSP, Kumar K, Verma PRP, Misra A,Verma RK, (2012) Molecular Pharmaceutics, 9(4): 1011-1016 (IF:4.48). DOI: 10.1021/mp300043f

  33. Exploiting 4-sulphate N-acetyl galactosamine decorated gelatin nanoparticles for effective targeting to professional phagocytes in vitro and in vivo.: Dwivedi P, Kansal S, Sharma M, Shukla R, Verma AK, Shukla P, Tripathi P, Gupta PK, Saini D, Dwivedi AK,Mishra PR, (2012) Journal of Drug Targeting (JDT), 20(10): 883-96. DOI: 10.3109/1061186X.2012.725169

  34. Inhalable Microparticles Containing Nitric Oxide Donors: Saying NO to Intracellular Mycobacterium Tuberculosis: Singh AK, Mohan M, Agrawal AK, Verma PRP, Gupta A ,Misra A,Verma RK, (2012) Molecular Pharmaceutics, 9(11): 3183-3187 (IF:4.48). DOI: 10.1021/mp300269g

  35. Loading and Release of Amphotericin-B from Biodegradable Poly (lactic-co-glycolic acid) Nanoparticles: Pandya S,Misra A, (2011) Journal Biomedical Nanotechnology (JBN), 7: 118-120. DOI: 10.1166/jbn.2011.1230

  36. Inhaled therapies for tuberculosis and the relevance of activation of lung macrophages by particulate drug delivery systems: Singh AK, Mohan M, Agrawal AK,Misra A, (2011) Therapeutic Delivery (Ther Delv.), 2(6): 753-768.. DOI: 10.4155/tde.11.34

  37. RGD modified albumin nanospheres for tumour vasculature targeting: Dubey PK, Singodia D,Vyas SP, (2011) Journal Pharmacy and Pharmacology (JPP), 63(1): 33-40. DOI: 10.1111/j.2042-7158.2010.01180.x

  38. Nanoparticles Containing Nitric Oxide Donor with Antileishmanial Agent for Synergistic Effect Against Visceral Leishmaniasis: Pandya S,Misra A, (2011) Journal Biomedical Nanotechnology (JBN), 213-215. DOI: 10.1166/jbn.2011.1274

  39. The devil's advocacy: When and why inhaled therapies for tuberculosis may not work: Yadav AB, Muttil P, Singh, Mohan M,Misra A, (2010) Tuberculosis ( Elsevier), 9: 65-66. DOI: 10.1016/j.tube.2010.10.001

  40. Microparticles induce variable levels of activation in macrophages infected with Mycobacterium tuberculosis: Yadav AB, Muttil P, Singh AK,Mohan M, Sinha SK,Misra A, (2010) Tuberculosis, 90: 188-196 (IF:3.00). DOI: 10.1016/j.tube.2010.03.001

  41. Inhalable Microparticles Containing Isoniazid and Rifabutin Target Macrophages and Stimulate the Phagocyte” to Achieve High Efficacy: Yadav AB, Sharma R, Muttil P, Singh AK, Mohan M, Patel SK, (2009) Indian journal of Experimental Biology (IJEB), 1.46: 469-474.

  42. Intracellular time course, Pharmacokinetics, and Biodistribution of Isoniazid and Rifabutin following Pulmonary delivery of inhalable Microparticles to Mice: Misra A,Kaur J, Kumar K, Yadav AB, (2008) Antimicrobial Agents and Chemotherapy (AAC), 52(9): 3195-3201. DOI: 10.1128/AAC.00153-08

  43. Apparatus for Pulmonary Delivery of Microparticles as a Dry Powder Inhalation Targeting Lung and Airway Macrophages in Mice: Kaur J, Muttil P, Kumar K, Yadav AB, Sharma R, Misra A, (2008) European Journal of Pharmaceutical sciences, 34: 56-65. DOI: 10.1016/j.ejps.2008.02.008

  1. Inhalable polymeric dry powders for antituberculosis drug delivery: Suneera Adlakha,Kalpesh Vaghasiya,Ankur Sharma,Eupa Ray,Rahul Kumar Verma, (2020) Nanotechnology based approaches for tuberculosis treatment, Elsevier, .

  2. Methods to Characterize Nanoparticles for Mucosal Drug Delivery: Kalpesh Vaghasiya Ankur Sharma Eupa Ray Suneera Adlakha Rahul Kumar Verma, (2020) Mucosal Delivery of Drugs and Biologics in Nanoparticles, Kalpesh Vaghasiya Ankur Sharma Eupa Ray Suneera Adlakha Rahul Kumar Verma.

  3. DNA nanostructures. chemistry, self-assembly and applica-tion, Emerging Applications of Nanoparticles and Architecture Nanostructures, Springer: Sharma A, Vaghasiya K, Yadav AB, (2018) .

  4. Molecular Medicines for Cancer: Concepts and Applications of Nanotechnology CRC Press/Taylor & Francis Publishers: Ray E, Sharma A, Vaghasiya K, (2018) .

  5. Lung anatomy and physiology and their implications for pul-monary drug delivery, Edited by-Nokhodchi and Martin, Pulmonary drug delivery: Advances and challenges, Wiley press, USA: Ibrahim M,Garcia-Contreras L., (2015) .

  6. Modulation of host pathogen inter-action following particle phagocytosis by infected macrophages In: Norazmi Mohd Nor, Armando Acosta and Maria Elena Sarmiento (Eds). The Art and Science of T: Singh Ak, Gupta A, Mohan M, Agrawal AK, Sharma R, Misra A, (2014) .

  1. Hybrid Nano-in-Micro systems for lung delivery of Host Defence Peptides (HDP) as ad-junct therapeutics for Pulmonary TB: Drug Delivery to Lungs Edinburg, (2017) .

  2. Hybrid Nano-in-Micro systems for lung delivery of Host Defence Peptides (HDP) as ad-junct therapeutics for Pulmonary TB: Sharma A, Verma RK, (2017) Drug Delivery to Lungs, 3: 113–115..

  3. Saying NO (Nitric Oxide) to Tuberculosis: INHALATION ASIA, (2015) .

  4. Lung Delivery of Anti-microbial Peptides (AMP) Using Dry Powder Inhalable Micro-spheres for Treatment of Pulmonary Tuberculosis: Respiratory drug delivery, (2015) .

  5. Development and validation of a HPLC method to determine concentrations of a novel anti-cancer compound, DT330 in biological samples AAPS: Raghuvanshi D, Bailey-Downs LC, Kunch A, Ihnat MA, and Garcia-Contreras L, (2013) .

  6. Optimization of Spray Freeze Drying Process Conditions to Prepare West Nile Virus Vaccine for Nasal Immunization AAPS: I brahim, Raghuvanshi D, Abraham SN, Staats HF, and Garcia-Contreras L, (2013) .

  7. Gupta P Quantitative PCR for persistent bacterial DNA following pulmonary delivery of microparticles Conference on Inhaled therapy for tuberculosis: Singh Ak, Mohan M, Agrawal AK, Misra A, Gupta UD, (2013) .

  8. Augmenting the macrophage nitric oxide response to intracellular Mycobacterium tuberculosis. Conference on Inhaled therapy for tuberculosis: Misra A, (2013) .

  9. Nitric oxide releasing PLGA nanoparticles: evaluation of antileishmanial activity. NanoBio-2012 Second International Conference on Nanotechnology and Molecular Medicine at Biomedical interfa: Pandya S, Khare P, Dube A, Verma PRP,Misra A, (2012) .

  10. Inhalable particles for value added drug delivery in tuberculosis: Singh AK, Heikham KD, Mohan M, Agrawal AK, Gupta A, (2011) INDO-US joint Symposium on Nanomedicine: Propects and Challenges, .

  11. the Academy of Pharmaceutical Sciences of Great Britain, University of Nottinghum, Nottinghum, UNITED KINGDOM(UK) (attended): Pharm Science, (2010) .

  12. Preclinical safety, efficacy and mechanism of action of inhaled microparticles containing anti-tuberculosis agents. Third indo-Japanese International Joint Symposium on overcoming interactabl: Sharma R, Muttil P, Yadav AB, Singh AK, Devi HK, Mohan M, Arora SK, Sen H, Sinha S, Suryakumar J, Modak V, Vineeth R, (2010) .

  13. Serendipitous activation of mouse and human macrophages infected with Mycobacterium tuberculosis on treatment with inhalable microparticles. An International Symposium on -Optimizations of I: Sharma R, Muttil P, Yadav AB, Singh AK, Mohan M, Misra A, (2009) .

  14. The devil's advocacy: When and why inhaled therapies for tuberculosis may not work. A International Symposium on -Optimizations of Inhaled Tuberculosis Therapies and Implications for Host-Pat: Misra A, Yadav AB, Singh AK, Mohan M, (2009) .

  15. Serum, tissue and intracellular concentrations following pulmonary delivery in rhesus macaques (Oral) International Symposium on -Optimizations of Inhaled Tuberculosis Therapies and Implicat: Misra A., (2009) .

  16. Inhalable poly lactide particles as drug carrier against tuberculosis (Oral presentation). NIPER Second Winter school 2009–Nanotechnology in advance Drug delivery, National Institute of Phar: Misra A, (2009) .

  17. Inhalable poly lactide particles as drug carrier against tuberculosis (Oral presentation). NIPER Second Winter school 2009–Nanotechnology in advance Drug delivery, National Institute of Phar: Misra A, (2009) .

  18. Microparticles specific for lung delivery: in-vivo drug distribution in monkeys. XVII International conference on Bioencapsulation-2009,Groningen, THE NETHERLANDS: Misra A., (2009) .

  19. Pharmacokinetic of PLA microparticles in Rhesus monkeys. XVI International conference on Bioencapsulation-2008, Dublin, IRELAND.: Kaur J, Yadav AB, Kumar K, Misra A., (2008) .

  20. PLA microparticles for pulmonary delivery of AntiTB drugs: biodistribution study. XVI International conference on Bioencapsulation-2008,Dublin, IRELAND: Kaur J, Yadav AB, Kumar K,Misra A., (2008) .

Fundings

  • Self-titrating inflammation-responsive injectable smart nano-formulations for repetitive delivery of DMARDs and corticosteroids against Rheumatoid Arthritis 3 years, DST-SERB(CRG )
    Funding Amount: 41 lakhs
    PI: Dr. Rahul K. Verma Co-PI: Dr. Rehan Khan
  • Enzyme activated targeted nano-formulations of autophagy/apoptosis-inducing bioactive as potential therapy for drug resistant lung cancer 2 years, Nanomission
    Funding Amount: 58 Lakhs
    PI: Dr. Rahul K. Verma
  • Pulmonary delivery of Host Defense Peptides (HDP) using Porous Nanoparticle-Aggregate Particles (PNAPs) for alveolar macrophage targeting in pulmonary tuberculosis 3 years, DST-SERB(YSS)
    Funding Amount: 27 lakhs
    PI: Dr. Rahul K. Verma
  • Metered dose transdermal Nano-Spray herbal gel formulation for rapid relief and effective management of cold injury at extreme altitudes 2 years, CARS(DIHAR-DRDO)
    Funding Amount: 9.95 lakhs
    PI: Dr. Rahul K. Verma
  • Enzyme-Responsive hydrogel for site-specific drug delivery as potential therapy for Colitis 3 years, DST-SERB- Core Research Grant
    Funding Amount: 43,22,120
    Role PI: Dr. Rehan Khan Role Co-PI: Dr. Rahul K. Verma

  • 2013

    Ph.D., Pharmaceutical Sciences

    Pharmaceutics division, Central Drug Research Institute (CDRI), Lucknow, India

  • 2005

    M.S.(Pharm.)

    National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India

  • 2003

    B. Pharmacy

    Ram-Eesh institute of Technology, Greater NOIDA, India

  • Scientist-D:Institute of Nano Science and Technology (INST), Mohali,, Punjab, India (January 2018 to Present till date )

  • Scientist-C:Institute of Nano Science and Technology (INST), Mohali,, Punjab, India (April 2014 to April 2017 )

  • Postdoctoral Researcher:Oklahoma University, Oklahoma City,, OK, USA (March 2013 to March 2014 )

  • Senior Research Fellow:Central Drug Research Institute (CDRI),, Lucknow, India (August 2009 to February 2014 )

  • Research Assistant:Central Drug Research Institute (CDRI),, Lucknow, India (January 2007 to August 2009 )

  • Senior Research Fellow:Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS),, Lucknow, India (September 2005 to November 2006 )

Awards & Honours

  • Royal Society of United Kingdom Fellowship UK- CSIR, INDIA-2009-10 – received to work in UK at Institute of pharmaceutical Innovation (IPI) Bradford University in year 2009-10.

  • Director’s Special CDRI incentive award-2008.

  • Bioencapsulation Research Group (BRG)- France travel Award 2009- received to travel and present at Groningen University, THE NETHERLANDS

  • Bioencapsulation Research Group (BRG)- France travel Award 2008- received to travel and present at Dublin City University, Dublin, IRELAND.

  • CSIR-SRF – Qualified Senior Research Fellowship-2009 (Council of Scientific & Industrial Research (CSIR), INDIA.

  • Post Graduate fellowship from NIPER during MS (Pharm) course (2003-2005)

  •  GATE (Graduate Aptitude Test for Engineering) -   Qualified in Pharmaceutical Sciences -2004.organized by Indian Institute of Technology (IIT), INDIA.


Professional Recognitions

© Copyright Institute of Nano Science and Technology 2014 - 2020 All Rights Reserved With Institute of Nano Science and Technology